Feb 2, 2021
Destiny Pharma Update On the Acquired NTCD-M3 Biotherapeutic Clinical Program For Prevention of Recurrence of C. diff. Infections (rCDI)
Destiny Pharma Update On the Acquired NTCD-M3 Biotherapeutic Clinical Program For Prevention of Recurrence of C. diff. Infections (rCDI)
Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections Press release by Destiny Pharma: Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical-stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces it is…
View On WordPress